Home2023-05-12T16:50:06-04:00

IMPALA Consortium

Inter-Company Quality Analytics

IMPALA aims to engage with Health Authorities inspectors on defining guiding principles for the use of advanced analytics to complement, enhance and accelerate current QA practices

IMPALA Consortium Icon Logo

The IMPALA ecosystem (industry, regulators, patients) will contribute to a change in paradigm for QA, i.e., where co-developed advanced analytics and best practices can help detect and mitigate issues faster, reduce the burden of retrospective, time-consuming traditional QA activities and ultimately accelerate approval and patient access to innovative drugs

Membership

  • Make valuable contributions to shift the quality assurance paradigm in the biopharmaceutical industry

  • Connect with experts across the industry

  • Enhance knowledge in areas of interest and expertise through work group projects
  • Access to members-only meetings, resources, materials, and work products prior to public publishing
  • Where relevant, be included in webinars, presentations, and press releases highlighting the work of the consortium
  • Be a part of the movement to accelerate approval and patient access to innovative drugs

Work Products

Publications

  • Clinical Safety Reporting

  • Audit Site Selection

  • Anomaly Detection in Clinical Data

  • Anomaly Detection in Audit Trial

  • RQA Workshop with Inspectors

  • DIA 2023 Workshop

  • 1 Publication

  • 1 Published Work Product

News / Events

The IMPALA Consortium provides the strategic focus for working across the Biopharmaceutical ecosystem to develop and gain industry-wide consensus for the adoption of improved QA using advanced analytics and best practices to be used across the industry; ultimately improving patient outcomes and quality care at greater efficiency and greater speed.

Copyright © | IMPALA Consortium.  All Rights Reserved.

Go to Top